Zydus Lifesciences Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Operating Revenue	262,432	232,415	195,474	172,374	151,099	144,035
Other Revenue	-1,539	-	-	-	-	-
Revenue	260,893	232,415	195,474	172,374	151,099	144,035
Revenue Growth (YoY)	17.27%	18.90%	13.40%	14.08%	4.90%	1.05%
Cost of Revenue	72,138	65,384	63,937	64,707	56,857	49,434
Gross Profit	188,755	167,031	131,537	107,667	94,242	94,601
Selling, General & Admin	56,238	51,539	42,454	37,648	32,472	31,237
Other Operating Expenses	58,202	46,726	36,047	34,263	29,873	29,299
Operating Expenses	125,821	107,429	86,145	79,139	69,501	67,245
Operating Income	62,934	59,602	45,392	28,528	24,741	27,356
Interest Expense	-3,201	-935	-440	-1,255	-1,144	-1,559
Interest & Investment Income	1,862	1,862	1,281	768	696	500
Earnings From Equity Investments	923	578	1,184	946	462	474
Currency Exchange Gain (Loss)	5,962	1,634	806	2,843	1,482	-92
Other Non Operating Income (Expenses)	1,895	31	-11	251	622	61
EBT Excluding Unusual Items	70,375	62,772	48,212	32,081	26,859	26,740
Merger & Restructuring Charges	-245	-	-177	-101	-	-
Impairment of Goodwill	-1,350	-1,350	-	-5,941	-	-
Gain (Loss) on Sale of Investments	590	590	1,385	596	874	-187
Gain (Loss) on Sale of Assets	345	345	134	208	-17	-36
Asset Writedown	-846	-846	-	-	-	-731
Other Unusual Items	-1,612	-666	-281	-	1,127	-1,320
Pretax Income	67,257	60,845	49,273	26,843	28,843	24,466
Income Tax Expense	16,995	14,119	9,775	5,878	5,117	1,936
Earnings From Continuing Operations	50,262	46,726	39,498	20,965	23,726	22,530
Earnings From Discontinued Operations	-	-	230	-46	22,457	-680
Net Income to Company	50,262	46,726	39,728	20,919	46,183	21,850
Minority Interest in Earnings	-878	-1,471	-1,133	-1,316	-1,310	-514
Net Income	49,384	45,255	38,595	19,603	44,873	21,336
Net Income to Common	49,384	45,255	38,595	19,603	44,873	21,336
Net Income Growth	8.85%	17.26%	96.88%	-56.31%	110.32%	81.34%
Shares Outstanding (Basic)	1,006	1,006	1,012	1,016	1,024	1,024
Shares Outstanding (Diluted)	1,006	1,006	1,012	1,016	1,024	1,024
Shares Change (YoY)	-0.11%	-0.56%	-0.37%	-0.79%	-	-
EPS (Basic)	49.07	44.97	38.14	19.30	43.83	20.84
EPS (Diluted)	49.07	44.97	38.14	19.30	43.83	20.84
EPS Growth	8.97%	17.92%	97.61%	-55.97%	110.32%	81.34%
Free Cash Flow	-	50,641	22,897	16,579	9,019	24,399
Free Cash Flow Per Share	-	50.33	22.63	16.32	8.81	23.83
Dividend Per Share	-	11.000	3.000	6.000	2.500	3.500
Dividend Growth	-	266.67%	-50.00%	140.00%	-28.57%	-
Gross Margin	72.35%	71.87%	67.29%	62.46%	62.37%	65.68%
Operating Margin	24.12%	25.64%	23.22%	16.55%	16.37%	18.99%
Profit Margin	18.93%	19.47%	19.74%	11.37%	29.70%	14.81%
Free Cash Flow Margin	-	21.79%	11.71%	9.62%	5.97%	16.94%
EBITDA	72,776	68,303	52,572	35,344	31,695	34,152
EBITDA Margin	27.89%	29.39%	26.90%	20.50%	20.98%	23.71%
D&A For EBITDA	9,842	8,701	7,180	6,816	6,954	6,796
EBIT	62,934	59,602	45,392	28,528	24,741	27,356
EBIT Margin	24.12%	25.64%	23.22%	16.55%	16.37%	18.99%
Effective Tax Rate	25.27%	23.21%	19.84%	21.90%	17.74%	7.91%
Revenue as Reported	265,452	235,110	198,315	174,240	153,346	144,491
Advertising Expenses	-	3,368	2,957	2,573	2,514	2,543

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.